Form 4: Emergent BioSolutions Director Kathryn C. Zoon Reports Stock and Option Grants

Director Kathryn C. Zoon reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc.

Summary

• Kathryn C. Zoon, a director of Emergent BioSolutions Inc., reported transactions related to the company's stock.
• On April 30, 2025, Zoon acquired 34,403 restricted stock units (RSUs) and 15,824 stock options as part of an annual grant for Board and Committee service.
• The RSUs will vest on the day prior to the one-year anniversary of the grant date, contingent on Zoon remaining a board member.
• Each RSU represents the right to receive one share of Emergent BioSolutions Inc. common stock upon vesting.
• The stock options, with an exercise price of $5.45, also vest on the same date and represent the right to purchase one share of common stock upon vesting.
• Following these transactions, Zoon beneficially owns 78,885 shares of common stock and 41,572 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the company and its shareholders.
• The vesting requirements incentivize continued service on the board of directors.

Future Outlook

The shares underlying the RSUs and options will vest on the day prior to the one-year anniversary of the grant date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Industry Context

This filing is a routine disclosure of stock and option grants to a company director, which is a common practice in publicly traded companies to incentivize and retain board members.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, including those in the biotechnology sector like Emergent BioSolutions.
• The vesting schedules and terms are generally consistent with industry norms for director compensation packages.
• Comparable companies such as Moderna, BioNTech, and Novavax also utilize stock options and RSUs as part of their director compensation.

Stakeholder Impact

• The grant of equity to a director aligns their interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.
• The vesting requirements incentivize the director to remain engaged and contribute to the company's success.

Key Dates

Keywords

Emergent BioSolutions, Director, Stock Options, RSUs, Kathryn C. Zoon, Beneficial Ownership, Form 4